A First-in-human, Two-part (Open Label, and Randomized/Double Blind/Placebo Controlled), Single- and Repeat-dose Study of CSJ137 in Erythropoietin-treated Chronic Hemodialysis Patients With Functional Iron-deficiency Anemia

Trial Profile

A First-in-human, Two-part (Open Label, and Randomized/Double Blind/Placebo Controlled), Single- and Repeat-dose Study of CSJ137 in Erythropoietin-treated Chronic Hemodialysis Patients With Functional Iron-deficiency Anemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs CSJ 137 (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 18 Aug 2018 to 1 Jul 2019.
    • 25 Jul 2017 Planned primary completion date changed from 18 Aug 2018 to 1 Jul 2019.
    • 10 May 2017 Planned number of patients changed from 96 to 88.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top